Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
about
Nonhuman genetics. Genomic basis for the convergent evolution of electric organsInvestigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophyResveratrol and MyopathyEarly pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells.Rescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouseLive imaging of muscle histolysis in Drosophila metamorphosisCharacterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophySatellite cells: regenerative mechanisms and applicability in muscular dystrophyBiomechanics of the sarcolemma and costameres in single skeletal muscle fibers from normal and dystrophin-null miceUtrophin up-regulation by an artificial transcription factor in transgenic miceRNA and diseaseInhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblastsEts-2 repressor factor silences extrasynaptic utrophin by N-box mediated repression in skeletal muscle.Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx miceIdentifying set-wise differential co-expression in gene expression microarray data.Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophiesGeneration of muscular dystrophy model rats with a CRISPR/Cas system.DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.New insights on contraction efficiency in patients with Duchenne muscular dystrophy.Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapiesUtroUp is a novel six zinc finger artificial transcription factor that recognises 18 base pairs of the utrophin promoter and efficiently drives utrophin upregulation.Stem cell transplantation for treating Duchenne muscular dystrophy: A Web of Science-based literature analysisTargeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regenerationRecombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells.Dysregulated mechanisms underlying Duchenne muscular dystrophy from co-expression network preservation analysisSuppression of premature termination codons as a therapeutic approach.Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice.Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophyHematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogsLong-term wheel running compromises diaphragm function but improves cardiac and plantarflexor function in the mdx mouseSplice-switching antisense oligonucleotides as therapeutic drugsRescue of skeletal muscle alpha-actin-null mice by cardiac (fetal) alpha-actin.Porcine Zygote Injection with Cas9/sgRNA Results in DMD-Modified Pig with Muscle Dystrophy.The neurobiology of the dystrophin-associated glycoprotein complex.Cell surface membrane proteins as personalized biomarkers: where we stand and where we are headed.Molecular pathways of pannexin1-mediated neurotoxicity.Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane.Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2.
P2860
Q22065593-20B7056B-66F6-49AD-99A6-05FA09D18F08Q24644090-5A00B3EC-DA2F-4CAD-855F-3EAF7C35ECDFQ26748160-60D1851F-1D9A-4096-A8E5-C52C293941FDQ27308743-D457916D-F926-4B37-A3EE-61D2D0BF6454Q27310125-16D5EC36-D129-4211-8ADA-2FD1B4C92518Q27318506-9D931851-07A8-4CB2-A2C3-CE214C9BA841Q27335054-A41741A6-1F1C-4014-A45C-A428B544B25AQ28083765-CC23EE0E-ABF3-4F62-BFFA-D02563F59386Q28305167-AEE8E6F7-C5E0-416C-AD9E-F5E9E567C141Q28469278-2FD2F2BB-9F60-40C3-8F32-27F3CB424F0FQ29615183-D90146EA-8385-4E04-9437-FB90CDFEF259Q31052506-0198E4E0-45C7-4D16-92E1-4D6297B16A8EQ33284878-FCC588CF-1F38-4FDC-BE15-EA4DA3876A27Q33290644-C8F4BC6E-1BC6-461F-BBF3-9A6D40630029Q33431020-EE285F98-511D-4B5D-A489-A12FB0191698Q33745227-91EC40FF-48A2-4BF3-BED3-EBD3D2494AD0Q33868949-76C171E6-9818-4DA3-95F2-04B45A1381BCQ33886594-12F62315-0E22-4A39-82A4-B7558A97B1A5Q33952122-B16F51C4-E07F-4889-9E22-C81F0BD49164Q34146934-D52F8D2A-161B-4B78-8A00-39193EE4E613Q34215825-B3085788-A5A3-4155-BCD6-B6A445C95329Q34567478-9F17E840-8BA5-4190-925F-F57F8D050565Q34997665-E51E573B-6755-48B4-B556-2669ACFF0F68Q35112511-0A586EBE-EA38-4FAE-8D21-6C70178C9A49Q35159846-7B74996F-E184-4EE9-A96A-14F513E4C2CDQ35583817-7C11721E-FB82-4301-8D96-81EBDDD77C4EQ36203719-74BE1418-8649-4873-9506-B4DB7E90DF79Q36598414-1B9DAAB4-6E7A-46E1-866E-F9BD4BDFCAE3Q36690467-9FF48566-66DF-418C-8375-6C76C7FC5E9CQ36841572-57ABB2BC-ED6A-4800-93A3-CF4EC70DCF5FQ36876597-DF652C8C-798E-4B99-A596-232794CC2A19Q37147219-3268BC56-FCC3-4249-895A-A8F6636C64AEQ37211004-95EF51CE-5CFE-4062-8D1C-DAA58EE401F2Q37264032-E30FD97F-7452-4B38-A709-9FB40DF5CE4DQ37377344-4B1D96B9-525C-4D1B-B05B-DD841CB31632Q37378530-6D489732-EB19-43AC-BAEE-80730881EDEDQ38138610-6BEEB772-7DF2-4F7D-9061-A505C46FD44EQ38191603-8FF13BFA-3545-4BAB-B9B4-915778731E82Q38424785-F4AE0593-9C71-4CB4-B5D4-EE7C4F3C0E40Q38700281-0C2DA06E-0FC6-4154-8694-4061F9F6DA18
P2860
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
@ast
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
@en
type
label
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
@ast
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
@en
prefLabel
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
@ast
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
@en
P2860
P356
P1433
P1476
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment
@en
P2093
Kay E Davies
Kristen J Nowak
P2860
P304
P356
10.1038/SJ.EMBOR.7400221
P577
2004-09-01T00:00:00Z